High, Katherine A.
Rockefeller University,
United States
2025 Rank: 17136
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Immunology
SubField 2:
Biotechnology
Rank in SubField 1: 600 out of 166615 Researchers
Data For The Year: 2025
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 17136 | 16982 |
| Total Cites | 27955 | 32546 |
| H-index | 76 | 85 |
| Hm-index | 28 | 30 |
| Number of Single Authored Papers | 26 | 26 |
| Total Cites to Single Authored Papers | 595 | 625 |
| Number of Single+First Authored Papers | 34 | 34 |
| Total Cites to Single+First Authored Papers | 1161 | 1207 |
| Number of Single+First+Last Authored Papers | 137 | 137 |
| Total Cites to Single+First+Last Authored Papers | 11513 | 13391 |
| Composite Score | 4 | 4 |
| Number of Distinct Citing Papers | 14673 | 15501 |
| Ratio of Total Citations to Distinct Citing Papers | 1.91 | 2.10 |
| Self-Citation Percentage |
14.11%
|
|
High, Katherine A.
Rockefeller University,
United States
2024 Rank: 17669
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Immunology
SubField 2:
Biotechnology
Rank in SubField 1: 630 out of 157372 Researchers
Data For The Year: 2024
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 17669 | 17505 |
| Total Cites | 25803 | 30194 |
| H-index | 73 | 82 |
| Hm-index | 28 | 29 |
| Number of Single Authored Papers | 25 | 25 |
| Total Cites to Single Authored Papers | 571 | 601 |
| Number of Single+First Authored Papers | 32 | 32 |
| Total Cites to Single+First Authored Papers | 986 | 1030 |
| Number of Single+First+Last Authored Papers | 133 | 133 |
| Total Cites to Single+First+Last Authored Papers | 10614 | 12426 |
| Composite Score | 4 | 4 |
| Number of Distinct Citing Papers | 13539 | 14327 |
| Ratio of Total Citations to Distinct Citing Papers | 1.91 | 2.11 |
| Self-Citation Percentage |
14.54%
|
|
High, Katherine A.
Spark Therapeutics, Inc.,
United States
2023 Rank: 16385
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Immunology
SubField 2:
Biotechnology
Rank in SubField 1: 596 out of 147556 Researchers
Data For The Year: 2023
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 16385 | 16190 |
| Total Cites | 23899 | 28136 |
| H-index | 70 | 80 |
| Hm-index | 28 | 29 |
| Number of Single Authored Papers | 26 | 26 |
| Total Cites to Single Authored Papers | 584 | 614 |
| Number of Single+First Authored Papers | 33 | 33 |
| Total Cites to Single+First Authored Papers | 983 | 1026 |
| Number of Single+First+Last Authored Papers | 133 | 133 |
| Total Cites to Single+First+Last Authored Papers | 9983 | 11771 |
| Composite Score | 4 | 4 |
| Number of Distinct Citing Papers | 12526 | 13287 |
| Ratio of Total Citations to Distinct Citing Papers | 1.91 | 2.12 |
| Self-Citation Percentage |
15.06%
|
|
High, Katherine A.
Spark Therapeutics, Inc.,
United States
2022 Rank: 16967
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Immunology
SubField 2:
Biotechnology
Rank in SubField 1: 631 out of 138599 Researchers
Data For The Year: 2022
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 16967 | 16542 |
| Total Cites | 21659 | 25754 |
| H-index | 68 | 78 |
| Hm-index | 27 | 28 |
| Number of Single Authored Papers | 25 | 25 |
| Total Cites to Single Authored Papers | 528 | 558 |
| Number of Single+First Authored Papers | 33 | 33 |
| Total Cites to Single+First Authored Papers | 839 | 882 |
| Number of Single+First+Last Authored Papers | 134 | 134 |
| Total Cites to Single+First+Last Authored Papers | 9101 | 10843 |
| Composite Score | 4 | 4 |
| Number of Distinct Citing Papers | 11363 | 12087 |
| Ratio of Total Citations to Distinct Citing Papers | 1.91 | 2.13 |
| Self-Citation Percentage |
15.90%
|
|
High, Katherine A.
Spark Therapeutics, Inc.,
United States
2021 Rank: 16719
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Immunology
SubField 2:
Biotechnology
Rank in SubField 1: 622 out of 127911 Researchers
Data For The Year: 2021
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 16719 | 16421 |
| Total Cites | 20642 | 24591 |
| H-index | 68 | 76 |
| Hm-index | 27 | 28 |
| Number of Single Authored Papers | 25 | 25 |
| Total Cites to Single Authored Papers | 512 | 542 |
| Number of Single+First Authored Papers | 33 | 33 |
| Total Cites to Single+First Authored Papers | 782 | 825 |
| Number of Single+First+Last Authored Papers | 133 | 133 |
| Total Cites to Single+First+Last Authored Papers | 8730 | 10425 |
| Composite Score | 4 | 4 |
| Number of Distinct Citing Papers | 10806 | 11503 |
| Ratio of Total Citations to Distinct Citing Papers | 1.91 | 2.14 |
| Self-Citation Percentage |
16.06%
|
|
High, Katherine A.
Spark Therapeutics, Inc.,
United States
2020 Rank: 17844
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Immunology
SubField 2:
Biotechnology
Rank in SubField 1: 651 out of 108509 Researchers
Data For The Year: 2020
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 17844 | 17115 |
| Total Cites | 17890 | 21521 |
| H-index | 63 | 71 |
| Hm-index | 26 | 27 |
| Number of Single Authored Papers | 29 | 29 |
| Total Cites to Single Authored Papers | 500 | 530 |
| Number of Single+First Authored Papers | 41 | 41 |
| Total Cites to Single+First Authored Papers | 664 | 705 |
| Number of Single+First+Last Authored Papers | 136 | 136 |
| Total Cites to Single+First+Last Authored Papers | 7676 | 9273 |
| Composite Score | 4 | 4 |
| Number of Distinct Citing Papers | 9242 | 9866 |
| Ratio of Total Citations to Distinct Citing Papers | 1.94 | 2.18 |
| Self-Citation Percentage |
16.87%
|
|
Partner with TOPSCINET
Reach science enthusiasts and researchers across the site. Write to business@topscinet.com and our marketing team will send a proposal built around your banner ad goals.